Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03494257 |
Recruitment Status :
Completed
First Posted : April 11, 2018
Last Update Posted : April 11, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study aims to evaluate the effect of fixed brinzolamide-brimonidine combination on intaocular pressure after uncomplicated phacoemulsification surgery.
Patients scheduled for phacoemulsification will be randomly assigned to 1 of 2 groups.
The treatment group will receive 1 drop of brimonidine-brinzolamide fixed combination immediately after surgery, and the control group will receive no treatment. The IOP will be measured preoperatively and at 6, 12, and 24 hours postoperatively.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cataract Intraocular Pressure | Drug: Brinzolamide-Brimonidine fixed combination | Not Applicable |
Phacoemulsification with the use of an ophthalmic viscosurgical device (OVD) and implantation of a foldable intraocular lens (IOL) is the preferred technique for cataract surgery today.
OVDs in spite of their advantages in phacoemulsification surgery, have been correlated with intraocular pressure (IOP) increase within the first 24 hours postoperatively. This constitutes a frequent short-term complication of cataract surgery and can lead to corneal edema and pain. This IOP rise may also increase the risk of retinal artery occlusion, ischemic optic neuropathy, and deterioration of preexisting glaucomatous nerve damage.
DuoVisc, an OVD that consists of Viscoat (chondroitin sulfate 4.0%-sodium hyaluronate 3.0%) in combination with Provisc (sodium hyaluronate 1.0%) is the most frequently used OVD during cataract surgery.
To prevent IOP spikes postoperatively, various antiglaucoma agents have been used. Brinzolamide is a carbonic anhydrase inhibitor that acts upon the ciliary processes and reduces aqueous humor secretion.Brimonidine is a highly selective a2-adrenergic agonist that increases uveoscleral outflow and reduces aqueous humor production.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 62 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Prospective randomized double-masked comparative study |
Masking: | Double (Participant, Investigator) |
Masking Description: | Patients will be unaware of their groupe assignment. The investigator who will measure the IOP will also be masked to group assignment. |
Primary Purpose: | Treatment |
Official Title: | Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification |
Actual Study Start Date : | September 4, 2017 |
Actual Primary Completion Date : | March 20, 2018 |
Actual Study Completion Date : | April 6, 2018 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Brinzolamide-Brimonidine fixed combination
1 drop of the brinzolamide-brimonidine fixed combination instilled in the patients cul de sac immediately after surgery
|
Drug: Brinzolamide-Brimonidine fixed combination
Simbrinza 0.2%-1% Ophthalmic Suspension
Other Name: Simbrinza, 0.2%-1% Ophthalmic Suspension |
No Intervention: No topical IOP reducing medication
No IOP reducing drops instilled after surgery
|
- IOP at 6 hours after surgery [ Time Frame: 6 hours postoperatively ]IOP will be measured by the same Goldman applanation tonometer used preoperatively
- IOP at 12 hours after surgery [ Time Frame: 12 hours postoperatively ]IOP will be measured by the same Goldman applanation tonometer used preoperatively
- IOP at 24 hours after surgery [ Time Frame: 12 hours postoperatively ]IOP will be measured by the same Goldman applanation tonometer used preoperatively

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients scheduled to undergo cataract surgery by phacoemulsification.
Exclusion Criteria:
- previous ocular surgery
- ocular hypertension
- pseudoexfoliation syndrome
- pigment dispersion syndrome
- glaucoma
- history of severe cardiovascular disease, cerebral or coronary insufficiency, depression, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans
- hypersensitivity to sulfonamides or brimonidine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03494257
Greece | |
University Hospital of Patras | |
Patra, Achaia, Greece, 26504 |
Principal Investigator: | Constantine Georgakopoulos, MD, PhD | Medical School, University of Patras, Greece |
Responsible Party: | Constantinos D. Georgakopoulos, MD, PhD, Associate Professor in Ophthalmology, University Hospital of Patras |
ClinicalTrials.gov Identifier: | NCT03494257 History of Changes |
Other Study ID Numbers: |
58/15.02.2018/5104 |
First Posted: | April 11, 2018 Key Record Dates |
Last Update Posted: | April 11, 2018 |
Last Verified: | April 2018 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
phacoemulsification intraocular pressure cataract |
brinzolamide brimonidinde fixed combination |
Cataract Lens Diseases Eye Diseases Brimonidine Tartrate Brinzolamide Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists |
Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors |